CS
IRWD icon

Credit Suisse’s Ironwood Pharmaceuticals IRWD Stock Holding History

Credit Suisse’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-27,104
Closed -$269K – 4641
2013
Q3 		$269K Buy
+27,104
New +$266K ﹤0.01% 3848

Other funds holding IRWD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Credit Suisse's IRWD Position: Q1 2024 in Review

Credit Suisse reduced its Ironwood Pharmaceuticals (IRWD) stake by 96% in Q1 2024, selling an estimated $65.7M and leaving 197,789 shares worth $1.72M. The position accounts for ﹤0.01% of the portfolio, ranked #1959.

Credit Suisse first reported a position in IRWD in Q2 2013 and has held it in 44 quarters since. The position peaked at $64.4M in Q4 2022. 261 funds tracked by Wall St. Rank hold IRWD as of Q1 2024.

  • Credit Suisse held 197,789 shares of Ironwood Pharmaceuticals worth $1.72M as of Q1 2024.
  • Credit Suisse sold 5,414,324 Ironwood Pharmaceuticals shares in Q1 2024, an estimated $65.7M.
  • Ironwood Pharmaceuticals made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #1959 holding.
  • Credit Suisse first reported a position in Ironwood Pharmaceuticals in Q2 2013 and has held it in 44 quarters since.
  • Credit Suisse's Ironwood Pharmaceuticals position peaked at $64.4M in Q4 2022.
  • 261 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.